TAGRISSO Reduced the Risk of Disease Recurrence in the Brain by 82% in the Adjuvant Treatment of Early-Stage EGFR-Mutated Lung Cancer
Saturday, September 19, 2020 - 6:04pm
Conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in patients with cardiac risk factors.
Key Points:
- Conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in patients with cardiac risk factors.
- For symptomatic congestive heart failure, permanently discontinue TAGRISSO
Keratitis was reported in 0.7% of 1142 patients treated with TAGRISSO in clinical trials. - Withhold TAGRISSO if SJS or EMM is suspected and permanently discontinue if confirmed
Verify pregnancy status of females of reproductive potential prior to initiating TAGRISSO. - Patients were treated with TAGRISSO 80 mg once-daily oral tablets or placebo for three years or until disease recurrence.